Epstein–Barr virus and COVID‐19

病毒 免疫学 病毒学 单核细胞增多症 淋巴瘤 共感染 医学 疾病 人口 爱泼斯坦-巴尔病毒 大流行 冠状病毒 传染病(医学专业) 2019年冠状病毒病(COVID-19) 内科学 环境卫生
作者
Arman Shafiee,Sepehr Aghajanian,Mohammad Mobin Teymouri Athar,Omid Kohandel Gargari
出处
期刊:Journal of Medical Virology [Wiley]
卷期号:94 (9): 4040-4042 被引量:21
标识
DOI:10.1002/jmv.27823
摘要

As the number of infections with the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rise beyond 430 million documented cases,1 the postinfection sequelae and long term symptoms of coronavirus disease 2019 (COVID-19) among the survivors has become a growing concern.2 The postacute sequelae of COVID-19 also called long COVID is a number of conditions and symptoms involving several organ systems including the immune system, hematological system, pulmonary and cardiovascular system, gastrointestinal system, and the nervous system, as well as general and constitutional symptoms such as fatigue, fever, and muscle weakness. While a number of studies have suggested the role of the autoimmune factors and persistence of viral fragments in the development of long-term COVID and failure to return to baseline health, the role of other latent host viruses has not been ruled out. Incidents of coinfection with COVID-19 and Epstein–Barr virus (EBV) in patients with aforementioned complications propose the hypothesis of EBV being one of the possible causative agents. The EBV is a double-stranded DNA virus of the herpes family best known as the agent responsible for infectious mononucleosis. Referred to as one of the most common viruses in humans, it has a ubiquitous distribution of 90% among the world population. As an oncogenic virus, it is associated with a variety of lymphoproliferative disorders such as Burkitt's lymphoma, Hodgkin's lymphoma, T and natural killer (NK) cell lymphomas, and nasopharyngeal carcinoma. It is characterized by lifelong latency in B cells and intermittent recrudescence of lytic infection caused by stressors.3, 4 The virus has the ability to switch from latent to lytic phase. The conversion process can be triggered by a variety of stimuli, including psychological stress. When the virus is reactivated, the patient may experience symptoms such as brain fog, fatigue, arthralgia, and skin rashes, among others. Recent studies suggest the possible interaction between SARS-CoV-2 and EBV. There have been a few hypothesizes regarding the mechanism of this interaction. One possible mechanism involves a decrease in CD8+ cells which are the primary cells responsible for immunity against EBV infection.5 Chen et al.6 found CD8+ count to be significantly lower in patients with SARS-CoV-2/EBV coinfection and proposed the idea of reactivation due to the decrease in CD8+ cells. A correlation between reduced CD8+ T cells and NK counts, EBV DNA levels, and COVID-19 severity was observed in Paolucci et al.'s7 study. Based on our systematic search of the MEDLINE database, we identified 11 studies reporting incidence of EBV reactivation during SARS-COV-2 pathogenicity. A meta-analysis was conducted to assess EBV reactivation incidence based on the available evidence. The analysis was carried out using R (version 4.1.3; R Core Team, 2020) and the metafor package (version 3.0.2).8 Our results included 993 COVID-19 patients, most of whom were in a severe or critical state. The pooled results demonstrate that the incidence of EBV reactivation is about 0.48 (95% confidence interval [CI]: 0.30–0.67; I2 = 97.02%). Our subgroup analysis based on patients' disease condition revealed an incidence of 0.66 (95% CI: 0.51–0.80; I2 = 90.97%) among critically ill patients and an incidence of 0.20 (95% CI: 0.13–0.28; I2 = 77.76%) among outpatients or patients without additional information with regard to disease severity (Figure 1). Further research is needed to determine the precise role of COVID-19 in the reactivation of latent EBV and the consequences of this reactivation. Recently, a longitudinal study on 309 COVID-19 patients showed that in addition to SARS-CoV-2 viremia, EBV viremia within 1–2 weeks of onset of COVID-19 is also associated with memory-related long COVID symptoms. EBV viremia in the same study has been solely attributed to fatigue and sputum as long COVID symptoms.9 The mechanisms through which EBV may influence the occurrence of long COVID could be attributed to the synergistic subversion and disruption of cellular and mitochondrial pathways. EBV encoded BZLF1 protein induces the degradation of p53 that normally governs DNA damage repair and apoptosis. Similarly, SARS-CoV-2 was also shown to degrade p53 in an Mdm2-independent manner through NSP3 expression and RCHY1 activation.10, 11 Furthermore, altered metabolic profile and mitochondrial biogenesis in both viruses10 can result in a sustained inflammatory response in SARS-CoV-2 and may mount EBV-induced fatigue in an already compromised individual.12 These would allow resurfacing of an otherwise latent EBV infection that may reside asymptomatically in its host. The potential role of EBV and its reactivation in the context of SARS-CoV-2 infection severity and long COVID is evident in the literature. Gold et al.3 published one of the first investigations on this topic. The authors suggested that the reactivation of the virus is observed soon after or within the initial phase of COVID-19 as demonstrated by positive titers of acute EBV infection antibodies in the screened individuals. The findings of this study reveal that 30% of COVID-19 patients showing symptoms of long-term COVID and SARS-CoV-2 may trigger other viruses that contribute to these symptoms. They reported the most frequent symptoms to be fatigue, insomnia, headaches, myalgia, and confusion, and found a direct relationship between the number of reported long COVID symptoms and early antigen-diffuse immunoglobulin G antibody titers.3 Drugs used in the treatment of COVID-19 may also play a major role in altering immune responses by means of regulating intracellular signaling pathways, thus prompting the reactivation process of EBV. The use of high-dose corticosteroids has been stated as a risk factor for herpes virus reactivation.13 Furthermore, lytic reactivation of EBV and Kaposi's sarcoma-associated herpesvirus (human herpes virus-8) and upregulation of viral lytic genes was seen in latently infected cells upon treatment with remdesivir in a dose-dependent manner.14 The results of the studies on the role of EBV and SARS-CoV-2 on disease severity has been conflicting. For instance, a previous study did not show increased disease severity in individuals with coinfection of EBV and SARS-CoV-2 and the results demonstrated no differences in terms of viral load and disease outcome.15 On the other hand, EBV coinfection was associated with increased incidence of fever, higher aspartate aminotransferase and C-reactive protein values, and corticosteroid use compared to SARS-CoV-2 infection alone in another study by Chen et al.6 EBV reactivation was also associated with a longer duration of Intensive care unit stay.16 However, stringent care is advised in evaluating the evidence of the causal association of EBV with COVID-19 severity or long COVID symptoms, considering the potential confounding effects of the high prevalence of EBV in the general population and the reactivation of other latent viruses in patients, such as herpes simplex virus, cytomegalovirus, Varicella zoster virus (VZV), human herpes virus-6 (HHV-6), and human herpes virus-7 (HHV-7).16, 17 Indeed, there have been reports regarding higher incidence of diseases associated with VZV and HHV-6 including Herpes zoster, Kawasaki disease, and pityriasis rosea during the pandemic period and/or along with coinciding SARS-CoV-2 infection.18 All of these supports that SARS-COV-2 infection may be a possible inducer of latent virus reactivation.17 Despite several studies have been published regarding EBV and COVID-19, the findings are not strong enough to establish a definite conclusion. Efforts need to be maintained to elucidate the impact of COVID-19 in the reactivation of latent EBV and the possible development of long COVID. In this context, prioritizing of COVID-19 vaccination must be addressed, and a history of COVID-19, even after complete recovery, should be recognized as a possible risk factor for EBV-associated post-COVID complications in the future management and monitoring of the patients. Sepehr Aghajanian, Mohammad M. T. Athar, Omid K. Gargari: Writing – original draft. Arman Shafiee: Conceptualization, investigation, project administration, Supervision, writing – review and editing. The authors declare no conflicts of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
木杉完成签到,获得积分10
1秒前
易烊千玺发布了新的文献求助10
1秒前
蒲公英发布了新的文献求助10
2秒前
2秒前
cccj发布了新的文献求助10
4秒前
幸福的鑫鹏完成签到 ,获得积分10
4秒前
Qiancheni发布了新的文献求助10
4秒前
Estella完成签到,获得积分10
7秒前
木杉发布了新的文献求助10
8秒前
易烊千玺完成签到,获得积分10
8秒前
8秒前
9秒前
科研牛人发布了新的文献求助10
10秒前
11秒前
CipherSage应助rz顺利毕业采纳,获得30
11秒前
沐沐心完成签到 ,获得积分10
11秒前
十二应助蒲公英采纳,获得10
13秒前
橘落不落发布了新的文献求助10
15秒前
jenningseastera应助linkman采纳,获得50
16秒前
TH完成签到,获得积分10
16秒前
17秒前
Smiling完成签到,获得积分10
18秒前
帕金森发布了新的文献求助50
18秒前
研友_alan完成签到,获得积分10
19秒前
大模型应助大聪明采纳,获得10
20秒前
南风完成签到,获得积分10
21秒前
22秒前
一支笔画天下完成签到,获得积分10
22秒前
23秒前
俊逸的石头完成签到,获得积分10
24秒前
解语花应助痴情的博超采纳,获得50
24秒前
cherlie应助yang采纳,获得10
26秒前
27秒前
哈哈哈完成签到,获得积分10
27秒前
香蕉觅云应助Dravia采纳,获得30
27秒前
椰椰完成签到,获得积分10
28秒前
fun完成签到 ,获得积分10
29秒前
wsh发布了新的文献求助10
29秒前
29秒前
li123完成签到,获得积分10
30秒前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 1370
Secondary Ion Mass Spectrometry: Basic Concepts, Instrumental Aspects, Applications and Trends 1000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
Comparison of adverse drug reactions of heparin and its derivates in the European Economic Area based on data from EudraVigilance between 2017 and 2021 500
[Relativity of the 5-year follow-up period as a criterion for cured cancer] 500
Statistical Analysis of fMRI Data, second edition (Mit Press) 2nd ed 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3945559
求助须知:如何正确求助?哪些是违规求助? 3490258
关于积分的说明 11055986
捐赠科研通 3221259
什么是DOI,文献DOI怎么找? 1780506
邀请新用户注册赠送积分活动 865536
科研通“疑难数据库(出版商)”最低求助积分说明 799886